HUMA earnings analysis
What we found in HUMA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Humacyte reported Q2 2026 revenue of $406,000, down from $495,000 sequentially and far below the $1,168,240 consensus estimate. EPS was a $0.16 loss, worse than the $0.09 loss in Q1 2026, while the filing provides no quantitative forward guidance. Cost reductions affecting approximately 45 employees and a Nasdaq bid-price deficiency requiring remediation by January 27, 2027 reinforce liquidity, execution and listing concerns.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue remains well below expectations
- Revenue was $406,000, down 18.0% from $495,000 in Q1 2026 but up 34.9% from $301,000 in Q2 2025. Revenue was also 65.3% below the $1,168,240 consensus estimate.
- EPS worsened sequentially
- Diluted EPS was a loss of $0.16 versus a loss of $0.09 in Q1 2026 and a loss of $0.24 in Q2 2025, indicating sequential deterioration but year-over-year improvement.
- Cost controls target operating expenses
- Management stated that it retained key personnel, resources and initiatives while reducing its workforce by approximately 45 employees in May 2026 as part of a cost-saving plan.
- Strategic Mayo Clinic agreement expanded
- The company issued Mayo Clinic warrants for 240,000 shares at an exercise price of $1.11 per share; the warrants vest in three annual tranches of 80,000 shares beginning March 31, 2027.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Cost reductions may disrupt execution
- In May 2026, the company reduced its workforce by approximately 45 employees. The filing warns that severance costs, employee attrition and loss of accumulated knowledge could adversely affect cash flow, productivity and execution.
- Nasdaq delisting risk
- Nasdaq notified the company on July 31, 2026 that its closing bid price was below the $1.00 minimum for 30 consecutive business days. Humacyte has until January 27, 2027, with an initial 180-calendar-day compliance period, to regain compliance.
- Potential insider-sale overhang
- The CEO adopted a Rule 10b5-1 plan allowing potential sales of up to 214,420 shares, with the first possible trade date of September 1, 2026. These potential sales could add equity-market overhang while the stock remains below Nasdaq’s $1.00 bid-price requirement.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.16
What they said about what is next.
No quantitative forward guidance was provided in the filing excerpt; the 10-Q does not state revenue or EPS outlook ranges.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Humacyte, Inc. reported a significant revenue miss and continued losses in its Q1 2026 results, with total revenue of $0.5 million, well below the estimated $1.4 million, and an EPS of -$0.13 matching consensus…
- 10-K · March 27, 2026
- Humacyte launched commercial sales of Symvess in Q1 2025 and reported $2.04 million of total revenue in 2025, including $1.39 million of product revenue, but remains deep in R&D and commercialization losses. The company…
- 10-Q · August 13, 2024
- Humacyte reported no revenue for the quarter and a larger net loss versus prior year driven by higher R&D and a large non-cash fair value increase in contingent liabilities. Cash increased to $93,563 but the company…
- 10-Q · November 10, 2022
- Humacyte reported Q3 2022 grant revenue of $31,000 (100% DoD), down from $241,000 in Q3 2021, and GAAP net loss per share improved to $(0.25) from $(0.72) a year ago. Operating loss widened to $(23.5) million for the…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing HUMA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever